Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
NATCOPHARM
Mr. Venkaiah Chowdary Nannapaneni M. Pharm, MS. · Hyderabad, India
₹935.95
▲+1.18%NATCOPHARM is trading near its 52-week low with a significant revenue decline but maintains healthy profitability and valuation metrics.
Exchange
NSI
Currency
INR
Day range
₹925.95 – ₹942.50
52-week range
₹789.00 – ₹1,226.80
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis75% confidence
The stock appears reasonably valued given its low P/E ratio of 11.82, though the significant revenue decline warrants caution.
23.7% below the 1-year high · trend up
Hedge-fund memo
Today
The stock is up 1.18% today, trading near the lower end of its day range.
This week
No specific weekly movement data provided.
This month
No specific monthly movement data provided.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Bullish
1 headlines · 1 outlets · 7d
Business Upturn·5d ago·Approval and March 2026 launch
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 4 recent quarters (EPS actual vs. consensus).
14.96 vs 7.69
94.54% surprise
8.46 vs 8.66667
-2.38% surprise
28.94 vs 24.555
17.86% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| NATCOPHARM | 167.64B | 11.82 | 16.85% | 10.44% | -39.60% |
| AJANTPHARM | 424.34B | 40.17 | 25.39% | 23.19% | 21.50% |
| APLLTD | 157.79B | 23.37 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Continued revenue decline in core business segments
Mitigation: Diversification into new therapeutic areas and geographies
Regulatory changes affecting pricing or market access
Mitigation: Proactive engagement with regulators and compliance measures
Business intelligence
Competitive moat
Established brand presence in the Indian pharmaceutical market with a focus on quality manufacturing practices.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Product pipeline approvals and launches
Earnings report showing revenue stabilization
Thesis builder
Bull case
Revenue growth could rebound with new product launches and market expansion opportunities.
Base case
Current valuation reflects the revenue decline, but profitability metrics remain attractive.
Bear case
Continued revenue decline could pressure margins and valuation further.
Time horizon
12-18 months
Est. CAGR
5-8%
Entry (qual.)
Consider on dips below 900 INR with confirmation of revenue stabilization
Exit (qual.)
Move above 1100 INR with sustained revenue growth above 10% YoY
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how NATCOPHARM fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain NATCOPHARM for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Hold with a cautious stance, monitoring for signs of revenue stabilization before considering accumulation.
Annual income statement, oldest → newest. Live via Yahoo.
26.84 vs 35.79
-25.01% surprise
| 12.36% |
| 7.39% |
| 4.40% |
| LAURUSLABS | 962.46B | 87.71 | — | 25.39% | 29.10% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹925.95
Resistance (day/52w high)
₹942.50
Volume
1,71,936
Trend
up
RSI (14)
41
MACD
bearish
MA cross
golden
50-day MA
₹956.00
200-day MA
₹944.64
vs 200-DMA
-0.9%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.